Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies

2010 ◽  
Vol 30 (3) ◽  
pp. 212-215 ◽  
Author(s):  
Stavros Sifakis ◽  
Ranjit Akolekar ◽  
Argyro Syngelaki ◽  
Jader De Cruz ◽  
Kypros H Nicolaides
Keyword(s):  
Growth Hormone ◽  
Trisomy 21 ◽  
Maternal Serum ◽  
Trisomy 18 ◽  
Placental Growth Hormone

First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18

2001 ◽  
Vol 21 (9) ◽  
pp. 718-722 ◽  
Author(s):  
Kevin Spencer ◽  
Adolfo W. Liao ◽  
Charas Y. T. Ong ◽  
Lut Geerts ◽  
Kypros H. Nicolaides
Keyword(s):  
Growth Factor ◽  
Trisomy 21 ◽  
First Trimester ◽  
Maternal Serum ◽  
Trisomy 18 ◽  
Placenta Growth Factor

Total amount of circulating human chorionic gonadotrophin α and β subunits in first trimester trisomies 21 and 18

1996 ◽  
Vol 148 (1) ◽  
pp. 27-31 ◽  
Author(s):  
E Jauniaux ◽  
K H Nicolaides ◽  
A-M Nagy ◽  
M Brizot ◽  
S Meuris
Keyword(s):  
Trisomy 21 ◽  
First Trimester ◽  
Maternal Serum ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Trisomy 18 ◽  
Serum Samples ◽  
Significant Difference ◽  
Common Unit ◽  
Α And Β Subunits

Abstract The aim of this study was to evaluate the variations in the balance between total (free and combined) circulating α and β subunits of human chorionic gonadotrophin (hCG) in trisomy 21 and 18. Maternal serum samples were collected at 10 and 11 weeks of gestation from 22 singleton pregnancies with trisomy 21 (n=17) and trisomy 18 (n=5) and 66 chromosomally normal controls, matched for gestational age. The hCG and free α and β subunits circulating levels were measured using specific immunoradiometric assays and converted in a common unit system obtained using calibration of the assays with intact and thermally dissociated purified hCG preparation. In trisomy 21, the only significant difference from controls was in the free βhCG level which was increased. In trisomy 18, intact hCG, free βhCG as well as total αhCG and total βhCG levels were significantly lower whereas the free αhCG level was significantly higher than in controls. The decrease in total βhCG was more pronounced than the decrease in total αhCG resulting in a significant increase in the total α- to βhCG subunit ratio in trisomy 18. These findings suggest some modifications in the biosynthesis and/or release rates of the hCG subunits in these trisomies. Journal of Endocrinology (1996) 148, 27–31

Maternal serum IGF-1, IGFBP-1 and 3, and placental growth hormone at 20 weeks’ gestation in pregnancies complicated by preeclampsia

2017 ◽  
Vol 10 ◽  
pp. 149-154 ◽  
Author(s):  
Shutan Liao ◽  
Mark H. Vickers ◽  
Rennae S. Taylor ◽  
Beatrix Jones ◽  
Mhoyra Fraser ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Maternal Serum ◽  
Placental Growth Hormone

scholarly journals Effect of Preanalytical Factors on the Stability of Maternal Serum Biomarkers and Calculated Risk for Trisomy 21, Trisomy 18, and Open Neural Tube Defect

2017 ◽  
Vol 1 (6) ◽  
pp. 690-701
Author(s):  
Brandon S. Walker ◽  
Vilte E. Barakauskas ◽  
David G. Grenache ◽  
Robert L. Schmidt
Keyword(s):  
Neural Tube ◽  
Neural Tube Defect ◽  
Trisomy 21 ◽  
Maternal Serum ◽  
Serum Biomarkers ◽  
Trisomy 18 ◽  
Calculated Risk ◽  
The Stability

Human Placental Growth Hormone Is Increased in Maternal Serum in Pregnancies Affected by Down Syndrome

2008 ◽  
Vol 23 (3) ◽  
pp. 211-216 ◽  
Author(s):  
Eleftheria Papadopoulou ◽  
Stavros Sifakis ◽  
Emmanuel Giahnakis ◽  
Yvoni Fragouli ◽  
Nikolaos Karkavitsas ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Down Syndrome ◽  
Maternal Serum ◽  
Placental Growth Hormone

DESIGN AN “IN-HOUSE” SOFTWARE FOR CALCULATING THE RISK OF TRISOMY 21, TRISOMY 18 AND OPEN NEURAL TUBE DEFECTS IN THE GESTATIONAL AGED 15 – 22 WEEKS

2011 ◽  
pp. 112-126
Author(s):  
Keyword(s):  
Down Syndrome ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Trisomy 21 ◽  
Parametric Method ◽  
Serum Markers ◽  
Maternal Serum ◽  
Trisomy 18 ◽  
Edwards Syndrome ◽  
Microsoft Office

Objectives: Design an “in-house” software for calculating the risk of fetus has Down syndrome, Edwards syndrome and open neural tube defects in prenatal screening at the gestational aged 15-22. Methods: Based on the Excel program of Microsoft Office and the articles with the Excel of Microsoft Office and related published articles, we design an “in-house” software based on maternal age, gestational age, history of having children with chromosomal aberrations and adjusted maternal serum markers AFP, hCG and uE3. The results were compared with the results of Prisca software by non-parametric method. Results: In cases having the risk of trisomy 21 with the range from 1/251 to 1/350: the risk tends to be lower than Prisca (83.7%). In cases having the high risks of trisomy 21 in screening but the results of prenatal diagnosis are not trisomy: the risks of “in house” software are lower than the risks of Prisca (73%) with 29% of cases has the risks less than 1/250 . In cases of trisomy 18 with the risks are lower than 1/150: there are no statistical significant differences between the two softwares (P<0.05). In screening open neural tube defects, the cases have the threshold higher than 1.50 MoM AFP: The results in the “in house” software tend to higher than Prisca (94%). The cases have the threshold lower than 1.50 MoM AFP: Where the disability screening of neural tube openings with thresholds lower than 1.5 MoM AFP: there are no statistical significant differences between the two softwares (P<0.05). Conclusion: The “in house” software has all the necessary functions for calculating the risk of Down syndrome, Edwards syndrome and open neural tube at the gestational aged 15-22.

Sign in / Sign up

Export Citation Format

Share Document